Medical Training
description
Transcript of Medical Training
![Page 1: Medical Training](https://reader036.fdocuments.us/reader036/viewer/2022062814/56816835550346895dddee7a/html5/thumbnails/1.jpg)
Medical Training
SPC & PIL
Pharmaco-vigilance
Medical Affairs Department
![Page 2: Medical Training](https://reader036.fdocuments.us/reader036/viewer/2022062814/56816835550346895dddee7a/html5/thumbnails/2.jpg)
![Page 3: Medical Training](https://reader036.fdocuments.us/reader036/viewer/2022062814/56816835550346895dddee7a/html5/thumbnails/3.jpg)
HYPERTENSIONhigh blood pressure
![Page 4: Medical Training](https://reader036.fdocuments.us/reader036/viewer/2022062814/56816835550346895dddee7a/html5/thumbnails/4.jpg)
Definition of Hypertension
![Page 5: Medical Training](https://reader036.fdocuments.us/reader036/viewer/2022062814/56816835550346895dddee7a/html5/thumbnails/5.jpg)
Chronic elevation of blood pressure.
140/90 mmHg
“Systemic, Arterial Blood Pressure”
![Page 6: Medical Training](https://reader036.fdocuments.us/reader036/viewer/2022062814/56816835550346895dddee7a/html5/thumbnails/6.jpg)
Blood pressure variation in the left ventricle (Blue line) & aorta (Red line) showing the cyclic variations of systolic and diastolic pressure
elastic recoil
![Page 7: Medical Training](https://reader036.fdocuments.us/reader036/viewer/2022062814/56816835550346895dddee7a/html5/thumbnails/7.jpg)
Etiology of Hypertension
![Page 8: Medical Training](https://reader036.fdocuments.us/reader036/viewer/2022062814/56816835550346895dddee7a/html5/thumbnails/8.jpg)
• Primary Hypertension “Essential Hypertension”
• Secondary Hypertension
95%
2ry to another medical condition
No identifiable cause
![Page 9: Medical Training](https://reader036.fdocuments.us/reader036/viewer/2022062814/56816835550346895dddee7a/html5/thumbnails/9.jpg)
Pheochromocytoma catecholamine
Cushing syndrome cortisol
Secondary Hypertension
Suprarenal: adenoma
![Page 10: Medical Training](https://reader036.fdocuments.us/reader036/viewer/2022062814/56816835550346895dddee7a/html5/thumbnails/10.jpg)
Cushing Syndrome
Suprarenal: adenoma
![Page 11: Medical Training](https://reader036.fdocuments.us/reader036/viewer/2022062814/56816835550346895dddee7a/html5/thumbnails/11.jpg)
Secondary Hypertension
Suprarenal: adenoma
Cushing Syndrome
![Page 12: Medical Training](https://reader036.fdocuments.us/reader036/viewer/2022062814/56816835550346895dddee7a/html5/thumbnails/12.jpg)
Polycystic Kidney
Secondary Hypertension
Renal: Tumors
![Page 13: Medical Training](https://reader036.fdocuments.us/reader036/viewer/2022062814/56816835550346895dddee7a/html5/thumbnails/13.jpg)
Secondary Hypertension
Renal: Renal Artery Stenosis
![Page 14: Medical Training](https://reader036.fdocuments.us/reader036/viewer/2022062814/56816835550346895dddee7a/html5/thumbnails/14.jpg)
Coarctation of Aorta
Secondary Hypertension
![Page 15: Medical Training](https://reader036.fdocuments.us/reader036/viewer/2022062814/56816835550346895dddee7a/html5/thumbnails/15.jpg)
![Page 16: Medical Training](https://reader036.fdocuments.us/reader036/viewer/2022062814/56816835550346895dddee7a/html5/thumbnails/16.jpg)
![Page 17: Medical Training](https://reader036.fdocuments.us/reader036/viewer/2022062814/56816835550346895dddee7a/html5/thumbnails/17.jpg)
![Page 18: Medical Training](https://reader036.fdocuments.us/reader036/viewer/2022062814/56816835550346895dddee7a/html5/thumbnails/18.jpg)
Liquorice 11β-hydroxysteroid dehydrogenase enzyme mineralocorticoid BP & K+
![Page 19: Medical Training](https://reader036.fdocuments.us/reader036/viewer/2022062814/56816835550346895dddee7a/html5/thumbnails/19.jpg)
Drugs
Secondary Hypertension
NSAIDsCOX2 selectiveSteroids
![Page 20: Medical Training](https://reader036.fdocuments.us/reader036/viewer/2022062814/56816835550346895dddee7a/html5/thumbnails/20.jpg)
Pregnancy
Secondary Hypertension
PIHPreclampsia “EPH gestosis”
![Page 21: Medical Training](https://reader036.fdocuments.us/reader036/viewer/2022062814/56816835550346895dddee7a/html5/thumbnails/21.jpg)
Sleeping Disturbance
Secondary Hypertension
• Tonsil enlargement • Postnasal adenoma • DNS • Obesity.
![Page 22: Medical Training](https://reader036.fdocuments.us/reader036/viewer/2022062814/56816835550346895dddee7a/html5/thumbnails/22.jpg)
Sleeping Disturbance
Secondary Hypertension
Management:Mandibular Advancement Splint (MAS), tonsillectomy, adenoidectomy, septoplasty or weight loss.
![Page 23: Medical Training](https://reader036.fdocuments.us/reader036/viewer/2022062814/56816835550346895dddee7a/html5/thumbnails/23.jpg)
Secondary Hypertension
HyperthyroidismHypothyroidism Ca
Other Causes:
![Page 24: Medical Training](https://reader036.fdocuments.us/reader036/viewer/2022062814/56816835550346895dddee7a/html5/thumbnails/24.jpg)
Rebound hypertension
Secondary Hypertension
Withdrawal ofClonidineBBs
![Page 25: Medical Training](https://reader036.fdocuments.us/reader036/viewer/2022062814/56816835550346895dddee7a/html5/thumbnails/25.jpg)
Diagnosis of Hypertension
![Page 26: Medical Training](https://reader036.fdocuments.us/reader036/viewer/2022062814/56816835550346895dddee7a/html5/thumbnails/26.jpg)
![Page 27: Medical Training](https://reader036.fdocuments.us/reader036/viewer/2022062814/56816835550346895dddee7a/html5/thumbnails/27.jpg)
Korotkoff soundsK1K2K3K4K5
![Page 28: Medical Training](https://reader036.fdocuments.us/reader036/viewer/2022062814/56816835550346895dddee7a/html5/thumbnails/28.jpg)
Symptoms & Signso No symptomso Symptoms of 1ry Cause (2ry hypertension)o Headache, Fatigue, Blurred Vision, Epistaxiso Nausea – Vomiting.o Retina : copper or silver wire appearance, exudates, hemorrhages or papilledema.
![Page 29: Medical Training](https://reader036.fdocuments.us/reader036/viewer/2022062814/56816835550346895dddee7a/html5/thumbnails/29.jpg)
Complications of Hypertension
![Page 30: Medical Training](https://reader036.fdocuments.us/reader036/viewer/2022062814/56816835550346895dddee7a/html5/thumbnails/30.jpg)
vasogenic edema
Metabolic Syndrome
nephrosclerosis
![Page 31: Medical Training](https://reader036.fdocuments.us/reader036/viewer/2022062814/56816835550346895dddee7a/html5/thumbnails/31.jpg)
Risk Factors of 1ry Hypertension
![Page 32: Medical Training](https://reader036.fdocuments.us/reader036/viewer/2022062814/56816835550346895dddee7a/html5/thumbnails/32.jpg)
Risk FactorsPrimary Hypertension
no identifiable reversible cause
o Sedentary lifestyleo Obesityo Insulin resistanceo Metabolic syndromeo Agingo Alcoholo Vitamin-D deficiency
![Page 33: Medical Training](https://reader036.fdocuments.us/reader036/viewer/2022062814/56816835550346895dddee7a/html5/thumbnails/33.jpg)
Risk FactorsPrimary Hypertension
o Low birth-weighto Family historyo Genetico Na+ sensitivityo Sympathetic overactivityo Renin overactivity
no identifiable reversible cause
![Page 34: Medical Training](https://reader036.fdocuments.us/reader036/viewer/2022062814/56816835550346895dddee7a/html5/thumbnails/34.jpg)
Pathophysiology Hypertension
![Page 35: Medical Training](https://reader036.fdocuments.us/reader036/viewer/2022062814/56816835550346895dddee7a/html5/thumbnails/35.jpg)
Factors Affecting Arterial Blood Pressure
![Page 36: Medical Training](https://reader036.fdocuments.us/reader036/viewer/2022062814/56816835550346895dddee7a/html5/thumbnails/36.jpg)
Management of Hypertension
![Page 37: Medical Training](https://reader036.fdocuments.us/reader036/viewer/2022062814/56816835550346895dddee7a/html5/thumbnails/37.jpg)
![Page 38: Medical Training](https://reader036.fdocuments.us/reader036/viewer/2022062814/56816835550346895dddee7a/html5/thumbnails/38.jpg)
ResistantHypertension
Failure to reduce blood pressure to the appropriate level after taking a 3-drug regimen including thiazide.
![Page 39: Medical Training](https://reader036.fdocuments.us/reader036/viewer/2022062814/56816835550346895dddee7a/html5/thumbnails/39.jpg)
Management of
Hypertension
![Page 40: Medical Training](https://reader036.fdocuments.us/reader036/viewer/2022062814/56816835550346895dddee7a/html5/thumbnails/40.jpg)
Prevention
![Page 41: Medical Training](https://reader036.fdocuments.us/reader036/viewer/2022062814/56816835550346895dddee7a/html5/thumbnails/41.jpg)
Lifestyle advice (non-pharmacological control)
Should be offered to the patient, before initiation of any drug therapy.
Lifestyle Changes
![Page 42: Medical Training](https://reader036.fdocuments.us/reader036/viewer/2022062814/56816835550346895dddee7a/html5/thumbnails/42.jpg)
Healthy Diet
Salt Restriction
DASH diet: (dietary approaches to
stop hypertension)
Rich in fruits & vegetables and low-fat or fat-free dairy foods.
![Page 43: Medical Training](https://reader036.fdocuments.us/reader036/viewer/2022062814/56816835550346895dddee7a/html5/thumbnails/43.jpg)
Weight Reduction
More ExerciseExercise
Reduce Stresses
![Page 44: Medical Training](https://reader036.fdocuments.us/reader036/viewer/2022062814/56816835550346895dddee7a/html5/thumbnails/44.jpg)
HypertensionManagement
Guidelines
![Page 45: Medical Training](https://reader036.fdocuments.us/reader036/viewer/2022062814/56816835550346895dddee7a/html5/thumbnails/45.jpg)
Lifestyle Changes “American & British Guidelines” suggest that:
Lifestyle changes should be explored in all patients who are hypertensive or pre-hypertensive.
![Page 46: Medical Training](https://reader036.fdocuments.us/reader036/viewer/2022062814/56816835550346895dddee7a/html5/thumbnails/46.jpg)
![Page 47: Medical Training](https://reader036.fdocuments.us/reader036/viewer/2022062814/56816835550346895dddee7a/html5/thumbnails/47.jpg)
![Page 48: Medical Training](https://reader036.fdocuments.us/reader036/viewer/2022062814/56816835550346895dddee7a/html5/thumbnails/48.jpg)
Classification of
Hypertension
![Page 49: Medical Training](https://reader036.fdocuments.us/reader036/viewer/2022062814/56816835550346895dddee7a/html5/thumbnails/49.jpg)
Classification of Hypertension
Systolic pressure
Diastolic pressure
mmHg mmHg
Normal 90–119 60–79Pre-hypertension 120–139 80–89Stage 1 140–159 90–99Stage 2 ≥160 ≥100Isolated systolic HT ≥140 <90
&
&
or
oror
![Page 50: Medical Training](https://reader036.fdocuments.us/reader036/viewer/2022062814/56816835550346895dddee7a/html5/thumbnails/50.jpg)
STROKEMIHF BY 40%
25%50%
AMERICAN GUIDELINES
![Page 51: Medical Training](https://reader036.fdocuments.us/reader036/viewer/2022062814/56816835550346895dddee7a/html5/thumbnails/51.jpg)
UK Hypertension GuidelinesStarting
Treatment threshold
Group Treatment Target
>160/100 All those with such persisting readings >160/100. <140/90
>140/90
Have established cardiovascular disease, or Have C.V. Risk (>20% per 10 years), or Have evidence end-organ damage without D.M., or Ch. renal dis., without Macroalbuminuria (or D.M.)
<140/90
>130/80 Type-2 Diabetes alone. <130/80
>135/85 Type-1 Diabetes alone. <130/80
>130/80Type-1 or 2 Diabetes with microalbuminuria. Type-1 or 2 Diabetes with renal, eye or CV damage.
<130/80
>130/80 Chronic renal disease with Macroalbuminuria. <125/75
![Page 52: Medical Training](https://reader036.fdocuments.us/reader036/viewer/2022062814/56816835550346895dddee7a/html5/thumbnails/52.jpg)
![Page 53: Medical Training](https://reader036.fdocuments.us/reader036/viewer/2022062814/56816835550346895dddee7a/html5/thumbnails/53.jpg)
![Page 54: Medical Training](https://reader036.fdocuments.us/reader036/viewer/2022062814/56816835550346895dddee7a/html5/thumbnails/54.jpg)
![Page 55: Medical Training](https://reader036.fdocuments.us/reader036/viewer/2022062814/56816835550346895dddee7a/html5/thumbnails/55.jpg)
COMPELLINGINDICATIONS
![Page 56: Medical Training](https://reader036.fdocuments.us/reader036/viewer/2022062814/56816835550346895dddee7a/html5/thumbnails/56.jpg)
Urine ALB/CR 2
DIABETIC HYPERTENSION
Diabetic Nephropathy with (Microalbuminuria)
ACEIs / ARBs.
Diabetic Nephropathy with (Macroalbuminuria)
ARBs / ACEIs.
Diabetic Hypertension without Nephropathy
ACEIs / ARBs +/- Thiazide +/- CCBs.
Urine ALB/CR 2
![Page 57: Medical Training](https://reader036.fdocuments.us/reader036/viewer/2022062814/56816835550346895dddee7a/html5/thumbnails/57.jpg)
Definition: [ GFR 60 ml / min / 1.73 m2 (= serum creatinine 1.5 mg / dL or 1.3 mg / dL )] [Albuminuria 300 mg/day (macroalbuminuria)].
Treatment Goal: Aggressive BP Lowering 125/75
Compelling Drug: ACEIs or ARBs (Diabetic or non-Diabetic Nephropathy). N.B. GFR (serum creatinine) up to 35% from baseline is acceptable , And is NOT a reason to withhold treatment unless hyperkalemia develops.
In Advanced Renal Disease: [= GFR 30 ml / min / 1.73 m2 (serum creatinine 2.5 - 3mg / dL)]:Increasing dose of loop diuretic is usually needed with ARBs or ACEIs)
CHRONIC RENAL DISEASE
![Page 58: Medical Training](https://reader036.fdocuments.us/reader036/viewer/2022062814/56816835550346895dddee7a/html5/thumbnails/58.jpg)
HEART FAILURE
Asymptomatic HF ACEIs / ARBs + BBs.
Advanced HF ACEIs / ARBs + BBs + Diuretic.
![Page 59: Medical Training](https://reader036.fdocuments.us/reader036/viewer/2022062814/56816835550346895dddee7a/html5/thumbnails/59.jpg)
CEREBRO-VASCULAR STROKE
Risks & Benefits of ACUTE Lowering of BP DURING acute CV Stroke are still unclear.
Control of BP at intermediate levels (approximately 160/100 mmHg) is appropriate until condition is stabilized or improved.
Stroke rates are lowered better by ACEIs / ARBs + Thiazide.
![Page 60: Medical Training](https://reader036.fdocuments.us/reader036/viewer/2022062814/56816835550346895dddee7a/html5/thumbnails/60.jpg)
ISCHEMIC HEART DISEASE
Asymptomatic Angina: BBs or CCBsSymptomatic Angina: ACE-Is / ARBs
(ARBs in Patients can’t tolerate ACE-Is)Acute MI (elevated ST segment): ACE-Is / ARBs + BBs
(ARBs in Patients can’t tolerate ACE-Is)
N.B. CCBs if given there should be extreme cautious to avoid heart failure.
![Page 61: Medical Training](https://reader036.fdocuments.us/reader036/viewer/2022062814/56816835550346895dddee7a/html5/thumbnails/61.jpg)
AA, aldosterone antagonist; ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin II-receptor blocker; βB, ß-blocker; CCB, calcium channel blocker; MI, myocardial infarction; CAD, coronary artery disease.
JAMA. 2004;289(19):2560-2572.
The Seventh Report of the Joint National Committee
Compelling Indications Diuretic ßB ACEI ARB CCB AA
Heart failure Post-MI
High CAD risk Diabetes
Chronic kidneydisease
Recurrent stroke
prevention
![Page 62: Medical Training](https://reader036.fdocuments.us/reader036/viewer/2022062814/56816835550346895dddee7a/html5/thumbnails/62.jpg)
Difference Between American & British Guidelines
![Page 63: Medical Training](https://reader036.fdocuments.us/reader036/viewer/2022062814/56816835550346895dddee7a/html5/thumbnails/63.jpg)
ThiazideACE-I ARB CCB BB
BB
ThiazideACE-I ARB CCB
American Guidelines
British Guidelines
![Page 64: Medical Training](https://reader036.fdocuments.us/reader036/viewer/2022062814/56816835550346895dddee7a/html5/thumbnails/64.jpg)
AntihypertensiveDrugs
![Page 65: Medical Training](https://reader036.fdocuments.us/reader036/viewer/2022062814/56816835550346895dddee7a/html5/thumbnails/65.jpg)
CLASSES OFANTIHYPERTENSIVE
DRUGS
![Page 66: Medical Training](https://reader036.fdocuments.us/reader036/viewer/2022062814/56816835550346895dddee7a/html5/thumbnails/66.jpg)
DIURETICS
![Page 67: Medical Training](https://reader036.fdocuments.us/reader036/viewer/2022062814/56816835550346895dddee7a/html5/thumbnails/67.jpg)
DIURETICSDrugs used to do forced diuresis.
INDICATIONS:o Treatment of Heart Failure.o Treatment of Hypertension.o Treatment of Liver cirrhosis.o Treatment of Certain Renal Conditions.o Urine Alkalinization To Treat Aspirin overdose:Acetazolamide ( carbonic anhydase H+ excretion)
The Use of Diuretics Require Electrolyte &
Acid-base Balance Monitoring
![Page 68: Medical Training](https://reader036.fdocuments.us/reader036/viewer/2022062814/56816835550346895dddee7a/html5/thumbnails/68.jpg)
DIURETICSTHIAZIDE DIURETIC:o Antihypertensive independent from its diuretic effect At a dose that causes diuresis. Due to Direct Vasodilator Effect Peripheral Resistance BP Afterload At dose causing diuresis Blood Volumevenous return Preload
o Compelling Indication in HF
o Least S.E.
![Page 69: Medical Training](https://reader036.fdocuments.us/reader036/viewer/2022062814/56816835550346895dddee7a/html5/thumbnails/69.jpg)
DIURETICSAdvantages of thiazide diuretic:o Least S.E.o Drug of 1st Choice in JNC7.o Causes synergism when combined with any antihypertensive therapy. o Compelling indication in HF.o Also Ca sparing diuretic.
![Page 70: Medical Training](https://reader036.fdocuments.us/reader036/viewer/2022062814/56816835550346895dddee7a/html5/thumbnails/70.jpg)
![Page 71: Medical Training](https://reader036.fdocuments.us/reader036/viewer/2022062814/56816835550346895dddee7a/html5/thumbnails/71.jpg)
Osmoticmannitol glucose
furosemide
HCTchlortalidone spironolactone
CAIacetazolamide
![Page 72: Medical Training](https://reader036.fdocuments.us/reader036/viewer/2022062814/56816835550346895dddee7a/html5/thumbnails/72.jpg)
Loop Diuretics
Lasix
o High Ceiling diuretic: “cause up to 20% increase in Na+ filtration load”
o Safer for Short term use only
Potassium Sparing Diureticso Used mainly to Correct Hypokalaemia “caused by other diuretics or digitalis”.
o Spironolactone AA: A compelling indication in HF.
![Page 73: Medical Training](https://reader036.fdocuments.us/reader036/viewer/2022062814/56816835550346895dddee7a/html5/thumbnails/73.jpg)
Adverse Effect Type of Diuretics Example Clinical EffectHypovolemia Loop Diuretic
ThiazideLasixHCT 25 mg/day
HypotensionThirst GFR
Hypokalemia Loop DiureticThiazideCarbonic Anhydrase Inhibitor
LasixHCT 25 mg/dayAcetazolamide
Muscle weaknessCardiac arrhythmia
Hyperkalemia Potassium Sparing Diuretics Spironolactone Muscle CrampsCardiac arrhythmia
Hyponatremia Loop DiureticThiazide
LasixHCT 25 mg/day
Neurological manifestations
Metabolic Alkalosis Loop DiureticThiazide
LasixHCT 25 mg/day
CNS manifestationsCardiac arrhythmia
Metabolic Acidosis Potassium Sparing Diuretics
CAI
Amilorides – triamtereneAcetazolamide
muscle weakness neurological symptomsseizures
Decrease Ca++ Excretion Thiazide HCT Prevents OsteoporosisPrevents Renal calculi
Hyperuricemia Loop Diuretic Lasix Gout
![Page 74: Medical Training](https://reader036.fdocuments.us/reader036/viewer/2022062814/56816835550346895dddee7a/html5/thumbnails/74.jpg)
α-blockers
![Page 75: Medical Training](https://reader036.fdocuments.us/reader036/viewer/2022062814/56816835550346895dddee7a/html5/thumbnails/75.jpg)
α-adrenergic receptors are present in the smooth muscles e.g. prostate, arteries & veins. α1 -adrenergic stimulation smooth muscles contraction vasoconstriction.α1-adrenergic blockers Relaxing vascular smooth muscles vasodilatation vascular resistance hypotension.α1-adrenergic blockers Relaxing prostate & U.B. neck.
α-blockers(α1 blockers or α1 antagonists)
![Page 76: Medical Training](https://reader036.fdocuments.us/reader036/viewer/2022062814/56816835550346895dddee7a/html5/thumbnails/76.jpg)
α-blockers(α1 blockers or α1 antagonists)
Other minor effects:Relaxing cardiac muscle COP hypotension.
Side effects:o Relaxing cardiac muscle Heart Failure.o Appetite obesityo Dryness of moutho Weak antihypertensive
![Page 77: Medical Training](https://reader036.fdocuments.us/reader036/viewer/2022062814/56816835550346895dddee7a/html5/thumbnails/77.jpg)
( HF events - ALLHAT)
![Page 78: Medical Training](https://reader036.fdocuments.us/reader036/viewer/2022062814/56816835550346895dddee7a/html5/thumbnails/78.jpg)
β-blockers
![Page 79: Medical Training](https://reader036.fdocuments.us/reader036/viewer/2022062814/56816835550346895dddee7a/html5/thumbnails/79.jpg)
β-blockers(β-blockers or β-antagonists)
β-adrenergic Receptors Location:o β1-adrenergic receptors mainly in : Heart & kidneys.
o β2-adrenergic receptors mainly in : Smooth muscles, (vascular – bronchial) Liver & Sk. Muscles.o β3-adrenergic receptors : Fat cells.
![Page 80: Medical Training](https://reader036.fdocuments.us/reader036/viewer/2022062814/56816835550346895dddee7a/html5/thumbnails/80.jpg)
β-blockers(β-blockers or β-antagonists)
o β2 : Bronchodilation. Vasodilatation. Affect Glycogen Breakdown in Liver & Skeletal muscles
o β3 : Lipolysis.
Renin Release BP.
Stimulation of β-adrenergic Receptors:o β1 : +ve Chronotropic on heart muscle. +ve Inotropic on heart muscle.
![Page 81: Medical Training](https://reader036.fdocuments.us/reader036/viewer/2022062814/56816835550346895dddee7a/html5/thumbnails/81.jpg)
β-blockers(β-blockers or β-antagonists)
Blocking of β-adrenergic Receptors By β-blockers :o β1 : Stress & Physical exertion effect on heart muscle. HR & Cardiac contractility force. Renin Release BP.
o β2 : Bronchospasm induces asthma Vasospasm BP. NB. (non selective β-blockers induce overall hypotension)
o β3 : Diabetogenic.
![Page 82: Medical Training](https://reader036.fdocuments.us/reader036/viewer/2022062814/56816835550346895dddee7a/html5/thumbnails/82.jpg)
β-blockers(β-blockers or β-antagonists)
( cardiac workload oxygen demand)
o Management of cardiac arrhythmias
( conduction & HR)
o Antihypertensive. ( COP & vascular resistance)
Indications of β-adrenergic blockers:o Cardio-protection after MI
![Page 83: Medical Training](https://reader036.fdocuments.us/reader036/viewer/2022062814/56816835550346895dddee7a/html5/thumbnails/83.jpg)
β-blockers(β-blockers or β-antagonists)
Side Effects of β-blockers :o Bronchospasm & dyspnea.o Diabetogenic Risk: disturbed glucose & lipid metabolism:Recent studies revealed that: Diuretics and β-blockers risk of diabetes ACE inhibitors & ARBs risk of diabetes.
That is why UK clinical guidelines :recommend avoiding diuretics and β-blockers as first-line treatment of hypertension.
![Page 84: Medical Training](https://reader036.fdocuments.us/reader036/viewer/2022062814/56816835550346895dddee7a/html5/thumbnails/84.jpg)
β-blockers(β-blockers or β-antagonists)
Other Side Effects of β-blockers :oHyperkalemia.o Erectile dysfunction.o Bradicardia, heart failure, heart block.o Hypotension, orthostatic hypotension.o Tremors.o Insomnia
Anti-Renin Effect
melatonin.
![Page 85: Medical Training](https://reader036.fdocuments.us/reader036/viewer/2022062814/56816835550346895dddee7a/html5/thumbnails/85.jpg)
![Page 86: Medical Training](https://reader036.fdocuments.us/reader036/viewer/2022062814/56816835550346895dddee7a/html5/thumbnails/86.jpg)
CCBs
![Page 87: Medical Training](https://reader036.fdocuments.us/reader036/viewer/2022062814/56816835550346895dddee7a/html5/thumbnails/87.jpg)
Calcium Channel-blockers (CCBs)Mode of Action: Disrupt the calcium ions (Ca+2) transport at calcium channels:o In vascular smooth muscles o In cardiac muscle
vascular resistance. contractility Stroke volume COP.
o In cardiac muscle HR
INDICATIONS:o Hypertension o Atrial flutter & AF BBs are better than CCBs
CCBs are better than BBs
o Angina vascular resistance BP contractility Work load & O2 demand
![Page 88: Medical Training](https://reader036.fdocuments.us/reader036/viewer/2022062814/56816835550346895dddee7a/html5/thumbnails/88.jpg)
Calcium Channel-blockers (CCBs)Side effects :o Headache. o Flushing. o Lower limb edema
o At high doses CCBs block the effect of insulin.
Contraindicated in HFo Direct Bradycardia.o Reflex Tachicardia:Direct vasodilatation stimulate baroreceptors HR(That’s why BBs are better in controlling AF)(That’s why CCBs better avoided in MI)
Side effects :o Headache. o Flushing. o Lower limb edema
![Page 89: Medical Training](https://reader036.fdocuments.us/reader036/viewer/2022062814/56816835550346895dddee7a/html5/thumbnails/89.jpg)
AnginaAF
Hypertension+ cardiotropic
![Page 90: Medical Training](https://reader036.fdocuments.us/reader036/viewer/2022062814/56816835550346895dddee7a/html5/thumbnails/90.jpg)
ACE-Is & ARBs
![Page 91: Medical Training](https://reader036.fdocuments.us/reader036/viewer/2022062814/56816835550346895dddee7a/html5/thumbnails/91.jpg)
Renin Angiotensin
Aldosterone
System
Renin Angiotensin
Aldosterone
System
R A AS
![Page 92: Medical Training](https://reader036.fdocuments.us/reader036/viewer/2022062814/56816835550346895dddee7a/html5/thumbnails/92.jpg)
Anatomy & PhysiologyOf Renal
Glomerulus
![Page 93: Medical Training](https://reader036.fdocuments.us/reader036/viewer/2022062814/56816835550346895dddee7a/html5/thumbnails/93.jpg)
Nephron
![Page 94: Medical Training](https://reader036.fdocuments.us/reader036/viewer/2022062814/56816835550346895dddee7a/html5/thumbnails/94.jpg)
GFRIGP
![Page 95: Medical Training](https://reader036.fdocuments.us/reader036/viewer/2022062814/56816835550346895dddee7a/html5/thumbnails/95.jpg)
![Page 96: Medical Training](https://reader036.fdocuments.us/reader036/viewer/2022062814/56816835550346895dddee7a/html5/thumbnails/96.jpg)
Glomerular Corpuscle
Juxta glomerular cells
macula densa
Afferent arteriole
Efferent arteriole
Distal convoluted tubule
Urinary chamber
Bowman’s capsuleBasement membrane -Podocytes
Proximal convoluted tubule
Urinary excretion: Fluid & electrolyte filtration from capillary side to urinary side through the basement membrane & podocytes to the urinary chamber of the glomerulus.
RENIN
BP
Na
BP
GFR
GFR
![Page 97: Medical Training](https://reader036.fdocuments.us/reader036/viewer/2022062814/56816835550346895dddee7a/html5/thumbnails/97.jpg)
Direct Na+ H2O retention
water retention Bl
ood
Bloo
d
Bloo
d
urine
urine
BP
GFR
![Page 98: Medical Training](https://reader036.fdocuments.us/reader036/viewer/2022062814/56816835550346895dddee7a/html5/thumbnails/98.jpg)
Direct Na+ H2O retention
water retention Bl
ood
Bloo
d
Bloo
d
urine
urine
BP
GFR
![Page 99: Medical Training](https://reader036.fdocuments.us/reader036/viewer/2022062814/56816835550346895dddee7a/html5/thumbnails/99.jpg)
Direct Na+ H2O retention
water retention
Bloo
dBl
ood
Bl
ood
urine
urine
BP
GFR
![Page 100: Medical Training](https://reader036.fdocuments.us/reader036/viewer/2022062814/56816835550346895dddee7a/html5/thumbnails/100.jpg)
GFRIGPAfferent vasodilatation
Efferent vasoconstriction
BP
RENIN
![Page 101: Medical Training](https://reader036.fdocuments.us/reader036/viewer/2022062814/56816835550346895dddee7a/html5/thumbnails/101.jpg)
Functional & Structural Changes of RAAS Activation
![Page 102: Medical Training](https://reader036.fdocuments.us/reader036/viewer/2022062814/56816835550346895dddee7a/html5/thumbnails/102.jpg)
Direct Na+ H2O retention
water retention Bl
ood
Bloo
d
Bloo
d
urine
urine
water retention
BP
GFR
BLOOD VOL
![Page 103: Medical Training](https://reader036.fdocuments.us/reader036/viewer/2022062814/56816835550346895dddee7a/html5/thumbnails/103.jpg)
GFRIGPAfferent vasodilatation
Efferent vasoconstriction
RENIN
BP
Functional ChangesIn HemodynamicsRenal Hyper-Filtration
![Page 104: Medical Training](https://reader036.fdocuments.us/reader036/viewer/2022062814/56816835550346895dddee7a/html5/thumbnails/104.jpg)
Magdi El-ShalakanyMean Arterial Pressure (mm Hg)
Intr
aglo
mer
ular
Pre
ssur
eChronic
hypertension with chronic
renal disease
Chronic hypertensionNormal
Low
High
80 120 160 18014010060
Renal Autoregulatory Curve
with normal renal function
![Page 105: Medical Training](https://reader036.fdocuments.us/reader036/viewer/2022062814/56816835550346895dddee7a/html5/thumbnails/105.jpg)
The Continuum of Diabetic
Nephropathy
![Page 106: Medical Training](https://reader036.fdocuments.us/reader036/viewer/2022062814/56816835550346895dddee7a/html5/thumbnails/106.jpg)
![Page 107: Medical Training](https://reader036.fdocuments.us/reader036/viewer/2022062814/56816835550346895dddee7a/html5/thumbnails/107.jpg)
Structural Changes of RAAS Activation
![Page 108: Medical Training](https://reader036.fdocuments.us/reader036/viewer/2022062814/56816835550346895dddee7a/html5/thumbnails/108.jpg)
RENAL CORPUSCLE
podocytesbasement membrane
Bowman's capsule
PCT
DCT
urinary Space
mesangial tissue
Juxtaglomerular cells
Macula densa
Juxta-Glomerular Apparatus
Renin
smooth muscle
cells
glomerular capillaries
![Page 109: Medical Training](https://reader036.fdocuments.us/reader036/viewer/2022062814/56816835550346895dddee7a/html5/thumbnails/109.jpg)
(afferent)(efferent)
RAAS STIMULATION1. Hypertension2. IGP3. Renal Hyperfiltration4. Renal Tissue injury5. Structural & Morphological
Changes :• Mesangial tissue expansion• Basement membrane thickening• Podocyte pedicles’ detachment• Intraglomerular Fibrosis
ACE-I1. BP2. IGP3. Renal t. injury4. GFR5. Bradykinin S.E:• Persist Dry Cough• Inflammation symp• Angio-edema
6. Tolerance
Degradation
![Page 110: Medical Training](https://reader036.fdocuments.us/reader036/viewer/2022062814/56816835550346895dddee7a/html5/thumbnails/110.jpg)
RAAS STIMULATION1. Hypertension2. Left Ventricular remodeling (CHF)3. IGP4.Renal Hyper-filtration5.Renal Tissue injury Chronic renal disease6.Structural & Morphological Changes :o Mesangial tissue expansiono Basement membrane thickeningo Podocytes pedicles’ detachmento Intraglomerular Fibrosis
![Page 111: Medical Training](https://reader036.fdocuments.us/reader036/viewer/2022062814/56816835550346895dddee7a/html5/thumbnails/111.jpg)
ACE-I EFFECTS1. BP2. sympathetic tone peripheral resistance3. Na+ & water retention blood volume 4. sympathetic tone HR5. COP & Heart work load & O2 consumption
ACE-I INDICATIONS1. Hypertension2. Heart Failure3. Angina4. Post myocardial infarction
Prophylaxis in Acute Coronary Syndrome
![Page 112: Medical Training](https://reader036.fdocuments.us/reader036/viewer/2022062814/56816835550346895dddee7a/html5/thumbnails/112.jpg)
ACE-I EFFECTS6. Intra-Glomerular Pressure (IGP)7. Renal Hyper-filtration8. Renal Tissue injury9. Improve functional & structural renal condition10. Structural & Morphological Changes11. micro & macro-albuminuria
ACE-I INDICATIONS5. Diabetic Nephropathy6. Chronic renal disease
Both due to BP & also independent to its Antihypertensive Effect
![Page 113: Medical Training](https://reader036.fdocuments.us/reader036/viewer/2022062814/56816835550346895dddee7a/html5/thumbnails/113.jpg)
ACE-I SIDE-EFFECTS1. Bradykinin & inflammatory related S.E:o Persistent Dry Cougho Angio-edemao Rash o Inflammation-related Pain
2. GFR Creatinine Clearance Rate (Ccr or C C) serum Creatinine
GFR (serum creatinine) up to 35% from baseline is acceptable & is NOT a reason to withhold treatment unless hyperkalemia develops.
3. Hyperkalemia
4. Metallic Taste (sulfhydryl part in Captopril molecule)
![Page 114: Medical Training](https://reader036.fdocuments.us/reader036/viewer/2022062814/56816835550346895dddee7a/html5/thumbnails/114.jpg)
1. Renal artery stenosis (bilateral)
2. Renal artery stenosis (Unilateral)3. Impaired renal function (ACE-Is may GFR).4. Aortic valve stenosis or cardiac outflow obstruction (ACE-I COP). 5. Hypovolemia or dehydration (ACE-Is diuresis ( fluid volume)
& BP).
6. Pregnancy (category D)
ACE-I ContraindicationsAbsolute Contraindications
Relative Contraindications
ACE-I is Contraindicated in Pregnancy
![Page 115: Medical Training](https://reader036.fdocuments.us/reader036/viewer/2022062814/56816835550346895dddee7a/html5/thumbnails/115.jpg)
Why ARBs Are Better than ACE-Is?
![Page 116: Medical Training](https://reader036.fdocuments.us/reader036/viewer/2022062814/56816835550346895dddee7a/html5/thumbnails/116.jpg)
(afferent)(efferent)
RAAS STIMULATION1. Hypertension2. IGP3. Renal Hyperfiltration4. Renal Tissue injury5. Structural & Morphological
Changes :• Mesangial tissue expansion• Basement membrane thickening• Podocyte pedicles’ detachment• Intraglomerular Fibrosis
ACE-I1. BP2. IGP3. Renal t. injury4. GFR C Cr5. Bradykinin S.E:• Persist Dry Cough• Inflammatory symptoms• Angio-edema
6. Tolerance
Degradation
![Page 117: Medical Training](https://reader036.fdocuments.us/reader036/viewer/2022062814/56816835550346895dddee7a/html5/thumbnails/117.jpg)
ARBs are better than ACE-Is1. No Bradykinin & inflammatory related S.E:
o Persistent Dry Cougho Angio-edemao Rash o Inflammation-related Pain
2. ARBs prevent excessive GFR Creatinine Clearance Rate which serum creatinine.
It Keeps the Drop in GFR & C cr (if occur) 35% from baseline which is acceptable & So No Need to Withhold treatment.
3. No Decline of Anti-Hypertensive Effect
4. No Metallic Taste (sulfhydryl part in Captopril molecule)
Beside All Benefits of ACE-Is
![Page 118: Medical Training](https://reader036.fdocuments.us/reader036/viewer/2022062814/56816835550346895dddee7a/html5/thumbnails/118.jpg)
![Page 119: Medical Training](https://reader036.fdocuments.us/reader036/viewer/2022062814/56816835550346895dddee7a/html5/thumbnails/119.jpg)
Factors Affecting Arterial Blood Pressure
Diuretics
Diuretics
α-blockers
β-blockers
β-blockers
CCBs
CCBs
CCBs
ACE-Is/ARBs
ACE-Is/ARBsACE-Is/ARBs
ACE-Is/ARBs
![Page 120: Medical Training](https://reader036.fdocuments.us/reader036/viewer/2022062814/56816835550346895dddee7a/html5/thumbnails/120.jpg)
ESH 2010: Possible Drug Combinations of Different Classes of Antihypertensive Agents
-blockers
-blockersCalcium
antagonists
AT1-receptorblockers
Diuretics
ACE inhibitors
The most effective and well tolerated combinations are shown as solid lines
ESH Guidelines. J Hypertens. 2007;25:1105-1087. ESH= European Society of Hypertension
![Page 121: Medical Training](https://reader036.fdocuments.us/reader036/viewer/2022062814/56816835550346895dddee7a/html5/thumbnails/121.jpg)
THANKYOU
![Page 122: Medical Training](https://reader036.fdocuments.us/reader036/viewer/2022062814/56816835550346895dddee7a/html5/thumbnails/122.jpg)
Renal Functions &
Renal Disease
![Page 123: Medical Training](https://reader036.fdocuments.us/reader036/viewer/2022062814/56816835550346895dddee7a/html5/thumbnails/123.jpg)
Renal Disease Terminologyo CRD = Chronic Renal Disease.o GFR = Glomerular Filtration Rate.o BUN = Blood Urea Nitrogen = Uremia = Azotemia.o ESRD = End Stage Renal Disease (= Need for Dialysis or Kidney Transplant)
![Page 124: Medical Training](https://reader036.fdocuments.us/reader036/viewer/2022062814/56816835550346895dddee7a/html5/thumbnails/124.jpg)
o Plasma concentrations of creatinine and urea (BUN = Blood Urea Nitrogen) are used to measure renal function.
Kidney Function Tests
o Creatinine clearance rate (CCr or CrCl): “A measure for GFR”.
o BUN and serum creatinine will not be raised normal Until 60% of total kidney function is lost.
o Creatinine clearance (CCr or CrCl) is then more accurate to measure suspected renal disease.
![Page 125: Medical Training](https://reader036.fdocuments.us/reader036/viewer/2022062814/56816835550346895dddee7a/html5/thumbnails/125.jpg)
Kidney Function Testso Proteinuria (elevated level of protein (albumin) in urine) : It is an important Prognostic marker for renal disease. o Albumin level 30 mg/24 hr urine is diagnostic for chronic kidney disease o Microalbuminuria is a level of 30-300 mg/24 hr urine; (can not be detected by usual urine dipstick methods).o Macroalbuminuria is a level 300 mg/24 hr urine.
![Page 126: Medical Training](https://reader036.fdocuments.us/reader036/viewer/2022062814/56816835550346895dddee7a/html5/thumbnails/126.jpg)
KEY MESSAGES OF AMERICAN GUIDELINES AND BRITISH GUIDLINES
![Page 127: Medical Training](https://reader036.fdocuments.us/reader036/viewer/2022062814/56816835550346895dddee7a/html5/thumbnails/127.jpg)
KEY MESSAGES OF AMERICAN GUIDELINES “JNC7”
1. In patients 50 yr : SBP ( 140 mmHg) is much more important Risk Factor for CVD than DBP.
2. CVD Risk doubles with each increment of 20/10 mmHg (above normal).
3. Pre-hypertensive patients (SBP 120-139 / DBP 80-89) Require Lifestyle modifications to CV Risk.
![Page 128: Medical Training](https://reader036.fdocuments.us/reader036/viewer/2022062814/56816835550346895dddee7a/html5/thumbnails/128.jpg)
KEY MESSAGES OF AMERICAN GUIDELINES “JNC7”
4. Thiazide diuretic is drug of First choice for most patients with uncomplicated hypertension.
5. Certain Risk conditions are Compelling Indications For Other Anti-hypertensive Agents (e.g. ACE-Is , ARBs , CCBs , BBs …. etc)
6. Most hypertensive patients will require 2 or more antihypertensive agents to Achieve Treatment Goals:
( 140/90 mmHg, or 130/80 mmHg for Diabetic or Chronic Renal disease patients )
7. If BP is 20/10 mmHg above Goal, consider additional agent therapy, one of which should be thiazide.
![Page 129: Medical Training](https://reader036.fdocuments.us/reader036/viewer/2022062814/56816835550346895dddee7a/html5/thumbnails/129.jpg)
KEY MESSAGES OF AMERICAN GUIDELINES “JNC7”
8. Empathy & Motivating Patients are very important to reach Treatment Goal.
9. Responsible Physician’s Judgment remains paramount in the presence of these guidelines.
![Page 130: Medical Training](https://reader036.fdocuments.us/reader036/viewer/2022062814/56816835550346895dddee7a/html5/thumbnails/130.jpg)
What Are The Main Differences In British
Guidelines?
![Page 131: Medical Training](https://reader036.fdocuments.us/reader036/viewer/2022062814/56816835550346895dddee7a/html5/thumbnails/131.jpg)
UK Guidelines Recommendations1. In hypertensive patients aged 55
or black patients of any age, the first choice for initial therapy should be either a CCB or a thiazide-type diuretic .
2. In hypertensive patients younger than 55, the first choice for initial therapy should be an ACE inhibitor /(ARBs).
![Page 132: Medical Training](https://reader036.fdocuments.us/reader036/viewer/2022062814/56816835550346895dddee7a/html5/thumbnails/132.jpg)
UK Guidelines Recommendations3. If initial therapy is a CCB or a
thiazide diuretic & a second drug is required, an ACE inhibitor /(ARBs) should be added.
4. If initial therapy was with an ACE-I or a CCB, a thiazide diuretic should be added.
![Page 133: Medical Training](https://reader036.fdocuments.us/reader036/viewer/2022062814/56816835550346895dddee7a/html5/thumbnails/133.jpg)
UK Guidelines Recommendations5. If treatment with three drugs is
required, the combination of ACE-I /(ARBs) , CCB, and thiazide diuretic should be used.6. If a fourth drug is required, one of the following should be considered:
a- A higher dose thiazide diuretic,
b- Another diuretic (with careful monitoring),
c- β-blockers, d- α-blockers.
![Page 134: Medical Training](https://reader036.fdocuments.us/reader036/viewer/2022062814/56816835550346895dddee7a/html5/thumbnails/134.jpg)
UK Guidelines Recommendations8. Beta blockers are not preferred as
initial therapy of hypertension. β-blockers may be considered in young
age, and those with intolerance or
contraindication to ACE inhibitors and ARBs: e.g. women with child-bearing potential.
![Page 135: Medical Training](https://reader036.fdocuments.us/reader036/viewer/2022062814/56816835550346895dddee7a/html5/thumbnails/135.jpg)
UK Guidelines Recommendations9. When a β-blockers is withdrawn,
dose should be stepped down gradually.
β-blockers should NOT be withdrawn in patients with compelling indications for β-blockers:
e.g. those who have symptomatic angina or who have had myocardial infarction.